78551-93-6 Usage
General Description
1-BOC-3-ISOBUTYLPIPERAZINE is a chemical compound that belongs to the class of piperazine derivatives. It is a derivative of piperazine with an isobutyl functional group attached to the nitrogen atom. The compound is also protected with a BOC (tert-butoxycarbonyl) group, which can be removed when needed. 1-BOC-3-ISOBUTYLPIPERAZINE has been used as a building block in the synthesis of various pharmaceuticals and bioactive compounds. It is often utilized in medicinal chemistry research for its potential biological activity and structural versatility. Additionally, it can be used in organic synthesis as a versatile intermediate in the production of various chemical compounds.
Check Digit Verification of cas no
The CAS Registry Mumber 78551-93-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,8,5,5 and 1 respectively; the second part has 2 digits, 9 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 78551-93:
(7*7)+(6*8)+(5*5)+(4*5)+(3*1)+(2*9)+(1*3)=166
166 % 10 = 6
So 78551-93-6 is a valid CAS Registry Number.
InChI:InChI=1/C13H26N2O2/c1-10(2)8-11-9-15(7-6-14-11)12(16)17-13(3,4)5/h10-11,14H,6-9H2,1-5H3
78551-93-6Relevant articles and documents
Expedite protocol for construction of chiral regioselectively N-protected monosubstituted piperazine, 1,4-diazepane, and 1,4-diazocane building blocks
Crestey, Francois,Witt, Matthias,Jaroszewski, Jerzy W.,Franzyk, Henrik
supporting information; experimental part, p. 5652 - 5655 (2009/12/08)
(Chemical Equation Presented) This paper describes the first study of solution-phase synthesis of chiral monosubstituted piperazine building blocks from nosylamide-activated aziridines. The protocol, involving aminolysis of the starting aziridines with ω-amino alcohols and subsequent Fukuyama-Mitsunobu cyclization, offers the advantage of mild conditions as well as short reaction times, and it leads to optically pure N-Boc- or N-Ns-protected piperazines. This four-step sequence, requiring only a single final chromatographic purification, was extended to include novel diazepane and diazocane derivatives.
